Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH276 plus cetuximab or chemotherapy in RAS-mutant advanced solid tumors and pancreatic ductal adenocarcinoma
CTR20262638Phase 2Active
- Sponsor
- GenFleet Therapeutics
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GFH276 in Nonhematologic neoplasms, pancreatic adenocarcinoma (PDAC), sponsored by GenFleet Therapeutics. Started Aug 2026; status: active.
02
Drugs
GFH276
03
Conditions
Nonhematologic neoplasmspancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20262638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262638.